Ionis licenses investigational Alzheimer’s therapy
- Thursday, December 19, 2019, 7:24
- PR Newswire
- Add a comment
CARLSBAD, Calif., Dec. 19, 2019 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively…
About the Author
admin has written 21643 stories on this site.